Portal de Periódicos da CAPES

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

2015; Elsevier BV; Volume: 125; Issue: 8 Linguagem: Inglês

10.1182/blood-2014-10-609032

1528-0020

Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan, Nelli Bejanyan, Mukta Arora, Claudio G. Brunstein, Bruce R. Blazar, Margaret L. MacMillan, Daniel J. Weisdorf,

T-cell and B-cell Immunology

Key Points GRFS is a new composite end point useful for comparing HCT techniques and represents ideal post-HCT recovery. In our cohort of 907 allogeneic HCT recipients, 1-year GRFS was 31%, with best outcomes in recipients of marrow from matched sibling donors.